Article

Erythromycin ophthalmic ointment 1 g launched

The FDA has approved Akorn Inc.?s erythromycin ophthalmic ointment USP 1 g as a supplement to the company?s already approved abbreviated new drug application for erythromycin ophthalmic ointment USP 3.5 g

Lake Forest, IL-The FDA has approved Akorn Inc.’s erythromycin ophthalmic ointment USP 1 g as a supplement to the company’s already approved abbreviated new drug application for erythromycin ophthalmic ointment USP 3.5 g, according to the company.

The company has begun shipping the product to its customers.

“Recent market shortages have made this an attractive product, [and it] is complementary to the other ophthalmic ointments Akorn currently sells,” said Raj Rai, chief executive officer of Akorn. “This approval gives us access to both the sizes of erythromycin ophthalmic ointment and positions us to compete effectively in all channels through which the product is sold.”

According to IMS Health, the annualized U.S. sales for erythromycin 1 g based on second quarter 2010 data were about $23 million.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.